NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Monday morning. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Trading Down 2.2 %

NBY stock opened at $0.59 on Monday. The business’s fifty day moving average price is $0.67 and its 200 day moving average price is $1.47. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $11.45. The company has a market capitalization of $2.92 million, a PE ratio of -0.01 and a beta of 0.73.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.